Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. develops and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. Company news centers on its advanced ceramics platform, FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, OsseoSculpt™ biologic, and SiNERGY™ silicon nitride/PEEK composite materials for patient-specific implant applications.
Recurring updates also cover commercialization milestones, first-in-human use of SINTX implants, strategic supply and private-label agreements, patent activity in antipathogenic materials, capital actions, operating efficiencies, and management or board changes. The company’s updates frame its current focus around medical-device applications, orthopedic and spine markets, U.S.-based manufacturing, and partnerships that extend the use of silicon nitride biomaterials.
SINTX Technologies has announced the awarding of four new international patents for antibacterial biomedical implants. These patents, granted in Canada, Australia (two patents), and Japan, enhance SINTX's intellectual property portfolio surrounding silicon nitride, a bioceramic noted for its bacteriostatic properties. The company aims to provide more value to its medical device partners, addressing significant healthcare issues related to infections. SINTX has also expanded through acquisitions, recently incorporating new ceramic materials into its offerings.
SINTX Technologies has received a $275k Phase I grant from the National Institutes of Health (NIH) to develop an antimicrobial trauma device. This 3D printed device will feature a carbon fiber reinforced polyetherketoneketone (PEKK) plate with embedded silicon nitride, enhancing its antibacterial properties. Collaborating with Drexel University and others, SINTX aims to address high infection rates in orthopedic trauma procedures. Successful development may lead to a Phase II award for commercialization. This marks NIH's third grant to SINTX within a year.
SINTX Technologies, Inc. (NASDAQ: SINT) announced a Phase II award of $1.1 million from the U.S. Department of Energy to develop 3D-printed alumina ceramic heat exchangers for HVAC systems. This award follows a successful Phase I effort by the company's subsidiary, Technology Assessment and Transfer (TA&T). The project aims to enhance energy efficiency in heating systems, boasting features such as lighter weight and superior thermal conductivity compared to conventional materials. Collaboration with the University of Cincinnati and Carrier is integral to advancing commercialization efforts.
SINTX Technologies, Inc. (NASDAQ: SINT) has announced the commencement of its rights offering subscription period, which has been extended to October 12, 2022. Each right allows the purchase of one unit at a subscription price of $1,000, including shares of Series D Convertible Preferred Stock and warrants. Maxim Group LLC is appointed as dealer-manager for this offering. The registration statement for this rights offering was declared effective by the SEC on September 23, 2022. Investors are advised to contact their brokers for participation details.
SINTX Technologies, Inc. (NASDAQ: SINT) announced a proposed rights offering aimed at security holders. Stock purchases must be completed by September 21, 2022, to be eligible for the offering. Each security holder will receive one non-transferable subscription right to purchase a unit for $1,000, which includes shares of Series D Convertible Preferred Stock and warrants. The subscription period runs from September 26, 2022, to October 10, 2022, unless extended. Maxim Group LLC is serving as the dealer-manager for the offering.
SINTX Technologies announced a successful 510(k) pre-submission meeting with the FDA regarding their FleX-SN PEEK spine implants. The FDA provided positive feedback on SINTX's regulatory strategies, allowing the company to proceed with its 510(k) filing and commercialization efforts. FleX-SN PEEK aims to enhance bone healing and reduce infection risks in surgical applications. The collaboration with Solvay has strengthened the product's efficacy. The company has been actively expanding its portfolio, including the acquisition of Technology Assessment & Transfer for other ceramic biomaterials.
SINTX Technologies and Oxford Performance Materials have developed a new orthopedic coating using PEKK and silicon nitride. This composite technology aims to address risks associated with metallic implants, such as infection and metal ion exposure. The coating enhances bone integration and resists bacterial adhesion, presenting an innovative solution for implants in orthopedics and dentistry. While the technology is FDA approved for individual components, further testing is underway to secure regulatory approval for the composite coating. Initial industry feedback has been positive, suggesting wide application potential.
SINTX Technologies announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T), enhancing its capabilities in the aerospace, defense, and biomedical markets. This strategic move is expected to generate immediate revenue for SINTX through TA&T’s existing relationships with commercial partners and the U.S. government. TA&T specializes in advanced ceramics, including 3D printing for medical devices and innovative materials for industrial applications. The acquisition aims to leverage synergies between the two companies to further their growth and success.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the filing of its 2021 Annual Report on Form 10-K with the SEC. The company has made significant investments in 2021 to expand its biomedical, industrial/armor, and antipathogenic business segments, focusing on revenue-generating opportunities, including armor materials and biomedical implants. A conference call is scheduled for April 13, 2022, to update stakeholders. SINTX manufactures advanced ceramics at its facilities in Salt Lake City, Utah, and is dedicated to developing advanced material-based solutions.
SINTX Technologies announced a $300k Phase 1 grant from the National Institutes of Health to develop 3D printed silicon nitride and polyetherketoneketone implants for craniomaxillofacial surgery. This collaboration with Drexel University and others aims to enhance implant performance by reducing failure rates linked to infections and poor integration. Over 235,000 CMF surgeries occur annually in the U.S. with a 5.5% failure rate. The grant supports the commercialization of this innovative material that could significantly improve patient outcomes.